<DOC>
	<DOCNO>NCT02116634</DOCNO>
	<brief_summary>Whether mesenchymal injection ALS patient effective ?</brief_summary>
	<brief_title>Mesenchymal Stem Cell Injection Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>After transplantation , patient visit experience neurologist evaluate EMG ( electromyography ) spirometry procedure clinical progression disease .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1. sporadic ALS accord escorial criterion 2. onset disease spinal cord involvement , Less 3 year disease onset disease progression 6 past month 3. mild moderate spinal bulbar disability , least score3 swallowing , 2 chew wake ALSFRS FVC ( functional vital capacity ) equal 50 % prediction amount 4. normal polysomnography 5 . Signed consent form 1. pregnancy lactation , 2. vascular disease , diabetes , systemic disease cancer , autoimmune , liver hematologic disease 3 . Hospitalization due serious illness last two month 4. survival time less two year 5 . Hypersensitivity component use cell culture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>